NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference

NeurAxis plans a webcast and virtual one-on-one investor meetings during the Lytham Partners Fall 2026 online conference.

Rhea-AI Summary

NeurAxis (NRXS) will present and meet with investors at the virtual Lytham Partners Fall 2026 Investor Conference on September 29-30, 2026.

The company’s webcast presentation is scheduled for 11:45 a.m. ET on Tuesday, September 29, 2026, and can be accessed via the conference site at https://lythampartners.com/fall2026/ or directly at https://app.webinar.net/lJ5aBmzWwkZ. A replay will be available after the event. Management will also participate in virtual one-on-one meetings with investors, which can be arranged by contacting Lytham Partners at 1x1@lythampartners.com or by registering at https://lythampartners.com/fall2026invreg/.

Argus Sep 16 session 35 alerts

+21.75% close to close 43.8x rel. volume Open Argus

Details

News Market Reaction – NRXS

+23.3% Peak in 3 hr 8 min

$93.68M Mkt Cap at Peak Alert

On Sep 16, the day this news came out, NRXS closed 21.75% above the previous close. Argus tracked a peak move of +23.3% during that session. Our momentum scanner recorded 35 alerts for this stock that day. Relative volume reached 43.8x the daily average during tracking.

Data tracked by StockTitan Argus for the Sep 16 session.

Key Figures

Conference dates: September 29-30, 2026 Webcast time: 11:45 a.m. ET

Conference dates

September 29-30, 2026

Lytham Partners Fall 2026 Investor Conference

Webcast time

11:45 a.m. ET

September 29, 2026

Key Terms

neuromodulation, percutaneous electrical nerve field stimulation, fda-cleared

3 terms

neuromodulation medical

"a medical technology company commercializing neuromodulation therapies"

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

percutaneous electrical nerve field stimulation medical

"its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology"

A non-surgical therapy that delivers small electrical pulses through the skin to stimulate specific peripheral nerves, usually via tiny adhesive electrodes placed near nerve-rich areas. Investors should care because devices and treatments using this method can open new markets or revenue streams if they gain clinical proof, regulatory approval, and reimbursement; conversely, their commercial success depends on safety data, patient acceptance, and competing options.

fda-cleared regulatory

"IB-Stim is FDA-cleared for functional abdominal pain"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

Company Webcast

The webcast presentation will take place at 11:45 a.m. ET on Tuesday, September 29, 2026. The webcast can be accessed by visiting the conference website at https://lythampartners.com/fall2026/ or directly at https://app.webinar.net/lJ5aBmzWwkZ. The webcast will also be available for replay following the event.

1x1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/fall2026invreg/.   

About NeurAxis, Inc.

NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of IB-Stim, its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA-cleared for functional abdominal pain in irritable bowel syndrome (IBS) and functional dyspepsia, including FD-linked nausea symptoms in patients ages 8 and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.

Contacts:

Company
NeurAxis, Inc.
info@neuraxis.com

Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How can investors access NeurAxis’s conference webcast?

The webcast at 11:45 a.m. ET on Tuesday, September 29, 2026, can be accessed through the Lytham conference website at https://lythampartners.com/fall2026/ or directly at https://app.webinar.net/lJ5aBmzWwkZ, and will be available for replay after the event.

How can investors schedule one-on-one meetings with NeurAxis management?

Virtual one-on-one meetings with NeurAxis management can be arranged by emailing Lytham Partners at 1x1@lythampartners.com or by registering for the event at https://lythampartners.com/fall2026invreg/.

What does NeurAxis focus on in its business?

NeurAxis focuses on neuromodulation therapies for chronic and debilitating conditions in children and adults and aims to drive adoption of IB-Stim, its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology.

For which indications is IB-Stim currently FDA-cleared?

IB-Stim is FDA-cleared for functional abdominal pain in irritable bowel syndrome (IBS) and functional dyspepsia, including FD-linked nausea symptoms, in patients ages 8 and older.